GlaxoSmithKline PakistanKAR:GLAXO +0.23%93 Days Inventory is 112.64 as of Mar. 2026, which is 28% above its 10-year median of 87.99. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨324.20 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 918 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 67.32% on this metric.
The historical rank and industry rank for GlaxoSmithKline Pakistan's Days Inventory or its related term are showing as below:
KAR:GLAXO'
s Days Inventory Range Over the Past 10 Years
Min: 78.96 Med: 87.99 Max: 125.92
Current: 125.92
During the past 13 years, GlaxoSmithKline Pakistan's highest Days Inventory was 125.92. The lowest was 78.96. And the median was 87.99.
KAR:GLAXO's Days Inventory is ranked better than 67.32% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs KAR:GLAXO: 125.92
Inventory Turnover measures how fast the company turns over its inventory within a year.
GlaxoSmithKline Pakistan's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GlaxoSmithKline Pakistan's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.77.
GlaxoSmithKline Pakistan (KAR:GLAXO) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
GlaxoSmithKline Pakistan's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
GlaxoSmithKline Pakistan's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
GlaxoSmithKline Pakistan Days Inventory Related Terms
GlaxoSmithKline Pakistan Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Days Inventory distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Days Inventory of 112.64 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 28% above median its historical median of 87.99. Over the past decade, GlaxoSmithKline Pakistan's Days Inventory has ranged from 78.96 to 125.92. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #300 out of 918 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is GlaxoSmithKline Pakistan's Days Inventory too high?
GlaxoSmithKline Pakistan's current Days Inventory of 112.64 is 28% above median its 10-year median of 87.99. Over the past 10 years, this metric has ranged from a low of 78.96 to a high of 125.92. The Drug Manufacturers industry median Days Inventory is 164.43. GlaxoSmithKline Pakistan's value of 112.64 is 31.5% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #300 out of 918 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #300 out of 918 companies for Days Inventory. This puts GlaxoSmithKline Pakistan in the upper half of its industry. The industry median Days Inventory is 164.43. GlaxoSmithKline Pakistan's value of 112.64 is 31.5% below this benchmark. Historically, GlaxoSmithKline Pakistan's own Days Inventory has ranged from 78.96 to 125.92 over the past decade. While the company's 10-year median is 87.99 vs. the industry median of 164.43, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Days Inventory of 112.64 is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Days Inventory is 112.64, which is 28% above median its own 10-year median of 87.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.20, compared to a current price of ₨376.99 — trading 16.3% above its estimated fair value. The current Days Inventory is 112.64, which is 28% above median its 10-year median of 87.99 and 31.5% below the Drug Manufacturers industry median of 164.43. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Days Inventory is 112.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨376.99 is trading 16.3% above its estimated GF Value™ of ₨324.20.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Days Inventory: 112.64 (28% above median its 10-year median of 87.99)
GF Value™: ₨324.20 vs. price of ₨376.99 (16.3% above fair value)
Industry Position: 31.5% below the Drug Manufacturers median (#300 of 918)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score
Get the complete analysis for KAR:GLAXO
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
